{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:19:47Z","timestamp":1783009187729,"version":"3.54.5"},"reference-count":84,"publisher":"Walter de Gruyter GmbH","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder that significantly predisposes individuals to delirium and dementia through multifaceted neurobiological pathways. The essence of this neurocognitive decline involves mechanisms such as central insulin resistance, chronic low-grade inflammation, and mitochondrial dysfunction. While metformin remains the cornerstone of T2DM management, its impact on the central nervous system exhibits a \u201cdouble-edged sword\u201d nature, balancing intrinsic neuroprotective properties against the potential neurotoxicity associated with vitamin B12 deficiency. This review aims to systematically synthesize epidemiological and clinical evidence linking metformin to neurocognitive outcomes, contrasting its efficacy with newer glucose-lowering agents such as GLP-1 receptor agonists and SGLT2 inhibitors. In addition, it sheds light on the reciprocal connectivity between systemic metabolic regulation and direct CNS modulation, specifically elucidating AMPK activation, the autophagy\u2013lysosome axis, and the gut\u2013brain and liver\u2013brain axes. We review these molecular mechanisms to delineate the delicate trade-off between neuroprotection and risk, providing a framework for precision pharmacotherapy and biomarker-guided stratification in high-risk T2DM populations.<\/jats:p>","DOI":"10.1515\/revneuro-2026-0013","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T18:59:54Z","timestamp":1777748394000},"page":"491-504","source":"Crossref","is-referenced-by-count":0,"title":["Metformin in T2DM: neurocognitive mechanisms and precision pharmacotherapy"],"prefix":"10.1515","volume":"37","author":[{"given":"ZeZhong","family":"Tang","sequence":"first","affiliation":[{"name":"Yan\u2019an Medical College, Yan\u2019an University , Baota District , Yan\u2019an 716000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiHeng","family":"Li","sequence":"additional","affiliation":[{"name":"Xi\u2019an Medical University , Xi\u2019an , P.R. 710003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiZhou","family":"Huang","sequence":"additional","affiliation":[{"name":"Xi\u2019an Medical University , Xi\u2019an , P.R. 710003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QianFa","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery , Xi\u2019an Central Hospital , West Fifth Street , Xi\u2019an 710003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyun","family":"Niu","sequence":"additional","affiliation":[{"name":"Key Laboratory for Space Bioscience & Biotechnology, School of Life Sciences, Northwestern Polytechnical University , Xi\u2019an 710000 , China"},{"name":"Department of Nuclear Medicine , Xi\u2019an Central Hospital, Xi\u2019an Jiaotong University , Xi\u2019an P.R.710003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SongNa","family":"Yin","sequence":"additional","affiliation":[{"name":"Yan\u2019an Medical College, Yan\u2019an University , Baota District , Yan\u2019an 716000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingJun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery , Xi\u2019an Central Hospital , West Fifth Street , Xi\u2019an 710003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026070214032334419_j_revneuro-2026-0013_ref_001","doi-asserted-by":"crossref","unstructured":"Adem, M.A., Decourt, B., and Sabbagh, M.N. (2024). Pharmacological approaches using diabetic drugs repurposed for Alzheimer\u2019s disease. Biomedicines 12: 99, https:\/\/doi.org\/10.3390\/biomedicines12010099.","DOI":"10.3390\/biomedicines12010099"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_002","doi-asserted-by":"crossref","unstructured":"Akiyama, N., Yamashiro, T., Ninomiya, I., Uemura, M., Hattori, Y., Ihara, M., Onodera, O., and Kanazawa, M. (2024). Neuroprotective effects of oral metformin before stroke on cerebral small-vessel disease. J.\u00a0Neurol. Sci. 456: 122812, https:\/\/doi.org\/10.1016\/j.jns.2023.122812.","DOI":"10.1016\/j.jns.2023.122812"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_003","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy, H.M., Al-Gareeb, A.I., Saad, H.M., and Batiha, G.E. (2023). Long-term use of metformin and Alzheimer\u2019s disease: beneficial or detrimental effects. Inflammopharmacology 31: 1107\u20131115, https:\/\/doi.org\/10.1007\/s10787-023-01163-7.","DOI":"10.1007\/s10787-023-01163-7"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_004","doi-asserted-by":"crossref","unstructured":"Alvarez, M., Prieto, A.E., Portilla, N., Moya, D., Rincon, O., and Guzman, I. (2025). Metformin-induced vitamin B12 deficiency: an underdiagnosed cause of diabetic neuropathy. World J.\u00a0Diabetes 16: 107514, https:\/\/doi.org\/10.4239\/wjd.v16.i7.107514.","DOI":"10.4239\/wjd.v16.i7.107514"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_006","doi-asserted-by":"crossref","unstructured":"Bailey, C.J. (2017). Metformin: historical overview. Diabetologia 60: 1566\u20131576, https:\/\/doi.org\/10.1007\/s00125-017-4318-z.","DOI":"10.1007\/s00125-017-4318-z"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_007","doi-asserted-by":"crossref","unstructured":"Cai, Z., Zhong, J., Zhu, G., and Zhang, J. (2025). Comparative efficacy and safety of antidiabetic agents in Alzheimer\u2019s disease: a network meta-analysis of randomized controlled trials. J.\u00a0Prev Alzheimers Dis. 12: 100111, https:\/\/doi.org\/10.1016\/j.tjpad.2025.100111.","DOI":"10.1016\/j.tjpad.2025.100111"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_008","doi-asserted-by":"crossref","unstructured":"Campagnoli, L.I.M., Varesi, A., Fahmideh, F., Hakimizad, R., Petkovic, P., Barbieri, A., Marchesi, N., and Pascale, A. (2025). From diabetes to degenerative diseases: the multifaceted action of metformin. Int. J.\u00a0Mol. Sci. 26: 9748, https:\/\/doi.org\/10.3390\/ijms26199748.","DOI":"10.3390\/ijms26199748"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_009","doi-asserted-by":"crossref","unstructured":"Campbell, J.M., Stephenson, M.D., de Courten, B., Chapman, I., Bellman, S.M., and Aromataris, E. (2018). Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J.\u00a0Alzheimers Dis. 65: 1225\u20131236, https:\/\/doi.org\/10.3233\/jad-180263.","DOI":"10.3233\/JAD-180263"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_010","doi-asserted-by":"crossref","unstructured":"Chavda, V., Yadav, D., Patel, S., and Song, M. (2024). Effects of a diabetic microenvironment on neurodegeneration: special focus on neurological cells. Brain Sci. 14: 284, https:\/\/doi.org\/10.3390\/brainsci14030284.","DOI":"10.3390\/brainsci14030284"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_011","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zhou, K., Wang, R., Liu, Y., Kwak, Y.D., Ma, T., Thompson, R.C., Zhao, Y., Smith, L., Gasparini, L., et al.. (2009). Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer\u2019s amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U. S. A. 106: 3907\u20133912, https:\/\/doi.org\/10.1073\/pnas.0807991106.","DOI":"10.1073\/pnas.0807991106"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_012","doi-asserted-by":"crossref","unstructured":"Chin-Hsiao, T. (2019). Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis. 10: 37\u201348, https:\/\/doi.org\/10.14336\/ad.2017.1202.","DOI":"10.14336\/AD.2017.1202"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_013","doi-asserted-by":"crossref","unstructured":"Cui, W., Lv, C., Geng, P., Fu, M., Zhou, W., Xiong, M., and Li, T. (2024). Novel targets and therapies of metformin in dementia: old drug, new insights. Front. Pharmacol. 15: 1415740, https:\/\/doi.org\/10.3389\/fphar.2024.1415740.","DOI":"10.3389\/fphar.2024.1415740"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_014","doi-asserted-by":"crossref","unstructured":"de la Monte, S.M. and Wands, J.R. (2008). Alzheimer\u2019s disease is type 3\u00a0diabetes-evidence reviewed. J.\u00a0Diabetes Sci. Technol. 2: 1101\u20131113, https:\/\/doi.org\/10.1177\/193229680800200619.","DOI":"10.1177\/193229680800200619"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_015","doi-asserted-by":"crossref","unstructured":"de Mello, J.E., Teixeira, F.C., Dos Santos, A., Luduvico, K., Soares de Aguiar, M.S., Domingues, W.B., Campos, V.F., Tavares, R.G., Schneider, A., Stefanello, F.M., et al.. (2024). Treatment with blackberry extract and metformin in sporadic Alzheimer\u2019s disease model: impact on memory, inflammation, redox status, phosphorylated tau protein and insulin signaling. Mol. Neurobiol. 61: 7814\u20137829, https:\/\/doi.org\/10.1007\/s12035-024-04062-2.","DOI":"10.1007\/s12035-024-04062-2"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_016","doi-asserted-by":"crossref","unstructured":"Dove, A., Shang, Y., Xu, W., Grande, G., Laukka, E.J., Fratiglioni, L., and Marseglia, A. (2021). The impact of diabetes on cognitive impairment and its progression to dementia. Alzheimer Dement 17: 1769\u20131778, https:\/\/doi.org\/10.1002\/alz.12482.","DOI":"10.1002\/alz.12482"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_017","doi-asserted-by":"crossref","unstructured":"Du, M.R., Gao, Q.Y., Liu, C.L., Bai, L.Y., Li, T., and Wei, F.L. (2022). Exploring the pharmacological potential of metformin for neurodegenerative diseases. Front Aging Neurosci. 14: 838173, https:\/\/doi.org\/10.3389\/fnagi.2022.838173.","DOI":"10.3389\/fnagi.2022.838173"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_018","doi-asserted-by":"crossref","unstructured":"Dutta, S., Shah, R.B., Singhal, S., Dutta, S.B., Bansal, S., Sinha, S., and Haque, M. (2023). Metformin: a review of potential mechanism and therapeutic utility beyond diabetes. Drug Design Develop. Ther. 17: 1907\u20131932, https:\/\/doi.org\/10.2147\/dddt.s409373.","DOI":"10.2147\/DDDT.S409373"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_019","doi-asserted-by":"crossref","unstructured":"Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., and Morris, A.D. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304\u20131305, https:\/\/doi.org\/10.1136\/bmj.38415.708634.f7.","DOI":"10.1136\/bmj.38415.708634.F7"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_020","doi-asserted-by":"crossref","unstructured":"Fang, W., Zhang, J., Hong, L., Huang, W., Dai, X., Ye, Q., and annd Chen, X. (2020). Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK\/CREB-mediated histone acetylation. J.\u00a0Affect. Disord. 260: 302\u2013313, https:\/\/doi.org\/10.1016\/j.jad.2019.09.013.","DOI":"10.1016\/j.jad.2019.09.013"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_021","doi-asserted-by":"crossref","unstructured":"Galal, M.A., Al-Rimawi, M., Hajeer, A., Dahman, H., Alouch, S., and Aljada, A. (2024). Metformin: a dual-role player in cancer treatment and prevention. Int. J.\u00a0Mol. Sci. 25: 4083, https:\/\/doi.org\/10.3390\/ijms25074083.","DOI":"10.3390\/ijms25074083"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_022","doi-asserted-by":"crossref","unstructured":"Geng, C., Meng, K., Zhao, B., Liu, X., and Tang, Y. (2024). Causal relationships between type 1 diabetes mellitus and Alzheimer\u2019s disease and Parkinson\u2019s disease: a bidirectional two-sample Mendelian randomization study. Eur. J.\u00a0Med. Res. 29: 53, https:\/\/doi.org\/10.1186\/s40001-023-01628-z.","DOI":"10.1186\/s40001-023-01628-z"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_023","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez P\u00e9rez, N., Bellotto, M., Porte Alc\u00f3n, S., Bentivegna, M., Arcucci, L., Vinuesa, \u00c1., Presa, J., Brites, F., P\u00e9rez Sirkin, D., Beauquis, J., et al.. (2025). Metformin protects against insulin resistance-related dementia risk involving restored microglial homeostasis. Life Sci. 378: 123803, https:\/\/doi.org\/10.1016\/j.lfs.2025.123803.","DOI":"10.1016\/j.lfs.2025.123803"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_024","doi-asserted-by":"crossref","unstructured":"Herv\u00e1s, D., Forn\u00e9s-Ferrer, V., G\u00f3mez-Escribano, A.P., Sequedo, M.D., Peir\u00f3, C., Mill\u00e1n, J.M., and V\u00e1zquez-Manrique, R.P. (2017). Metformin intake associates with better cognitive function in patients with Huntington\u2019s disease. PLoS One 12: e0179283, https:\/\/doi.org\/10.1371\/journal.pone.0179283.","DOI":"10.1371\/journal.pone.0179283"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_025","doi-asserted-by":"crossref","unstructured":"Hsieh, T.C., Chen, H.H., Chang, W.C., and Ho, C.P. (2025). Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: a population-based study. Alzheimers Dement. 21: e70590, https:\/\/doi.org\/10.1002\/alz.70590.","DOI":"10.1002\/alz.70590"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_026","doi-asserted-by":"crossref","unstructured":"Hu, T., Wei, J.W., Zheng, J.Y., Luo, Q.Y., Hu, X.R., Du, Q., Cai, Y.F., and Zhang, S.J. (2024). Metformin improves cognitive dysfunction through SIRT1\/NLRP3\u00a0pathway-mediated neuroinflammation in db\/db mice. J.\u00a0Mol. Med. 102: 1101\u20131115, https:\/\/doi.org\/10.1007\/s00109-024-02465-1.","DOI":"10.1007\/s00109-024-02465-1"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_027","doi-asserted-by":"crossref","unstructured":"Hui, E.K., Mukadam, N., Kohl, G., and Livingston, G. (2025). Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: a systematic review and meta-analysis. J.\u00a0Alzheimers Dis. 104: 627\u2013648, https:\/\/doi.org\/10.1177\/13872877251319054.","DOI":"10.1177\/13872877251319054"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_028","doi-asserted-by":"crossref","unstructured":"Inoue, K., Saliba, D., Gotanda, H., Moin, T., Mangione, C.M., Klomhaus, A.M., and Tsugawa, Y. (2025). Glucagon-like peptide-1 receptor agonists and incidence of dementia among older adults with type 2 diabetes: a target trial emulation. Ann. Intern. Med. 178: 1258\u20131267, https:\/\/doi.org\/10.7326\/annals-24-02648.","DOI":"10.7326\/ANNALS-24-02648"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_029","doi-asserted-by":"crossref","unstructured":"Jagust, W.J., Teunissen, C.E., and DeCarli, C. (2023). The complex pathway between amyloid \u03b2 and cognition: implications for therapy. Lancet Neurol. 22: 847\u2013857, https:\/\/doi.org\/10.1016\/s1474-4422(23)00128-x.","DOI":"10.1016\/S1474-4422(23)00128-X"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_030","doi-asserted-by":"crossref","unstructured":"Kciuk, M., Kruczkowska, W., Ga\u0142\u0119ziewska, J., Wanke, K., Ka\u0142uzi\u0144ska-Ko\u0142at, \u017b., Aleksandrowicz, M., and Kontek, R. (2024). Alzheimer\u2019s disease as type 3 diabetes: understanding the link and implications. Int. J.\u00a0Mol. Sci. 25: 11955, https:\/\/doi.org\/10.3390\/ijms252211955.","DOI":"10.3390\/ijms252211955"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_031","doi-asserted-by":"crossref","unstructured":"Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., Williamson, R., Fuchs, M., K\u00f6hler, A., Glossmann, H., et al.. (2010). Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. U. S. A. 107: 21830\u201321835, https:\/\/doi.org\/10.1073\/pnas.0912793107.","DOI":"10.1073\/pnas.0912793107"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_032","doi-asserted-by":"crossref","unstructured":"Kim, C., Kim, Y., Sohn, J.H., Sung, J.H., Han, S.W., Lee, M., Kim, Y., Lee, J.J., Mo, H.J., Yu, K.H., et al.. (2024). Effects of prior metformin use on stroke outcomes in diabetes patients with acute ischemic stroke receiving endovascular treatment. Biomedicines 12: 745, https:\/\/doi.org\/10.3390\/biomedicines12040745.","DOI":"10.3390\/biomedicines12040745"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_033","doi-asserted-by":"crossref","unstructured":"Koenig, A.M., Mechanic-Hamilton, D., Xie, S.X., Combs, M.F., Cappola, A.R., Xie, L., Detre, J.A., Wolk, D.A., and Arnold, S.E. (2017). Effects of the insulin sensitizer metformin in alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis. Assoc. Disord. 31: 107\u2013113, https:\/\/doi.org\/10.1097\/wad.0000000000000202.","DOI":"10.1097\/WAD.0000000000000202"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_034","doi-asserted-by":"crossref","unstructured":"Komici, K., Fantini, C., Santulli, G., Bencivenga, L., Femminella, G.D., Guerra, G., Mone, P., and Rengo, G. (2025). The role of diabetes mellitus on delirium onset: a systematic review and meta-analysis. Cardiovasc. Diabetol. 24: 216, https:\/\/doi.org\/10.1186\/s12933-025-02782-w.","DOI":"10.1186\/s12933-025-02782-w"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_035","doi-asserted-by":"crossref","unstructured":"Kruczkowska, W., Ga\u0142\u0119ziewska, J., Buczek, P., P\u0142uciennik, E., Kciuk, M., and \u015aliwi\u0144ska, A. (2025). Overview of metformin and neurodegeneration: a comprehensive review. Pharmaceuticals (Basel) 18: 486, https:\/\/doi.org\/10.3390\/ph18040486.","DOI":"10.3390\/ph18040486"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_036","doi-asserted-by":"crossref","unstructured":"Kumar, H., Chakrabarti, A., Sarma, P., Modi, M., Banerjee, D., Radotra, B.D., Bhatia, A., and Medhi, B. (2023). Novel therapeutic mechanism of action of metformin and its nanoformulation in Alzheimer\u2019s disease and role of AKT\/ERK\/GSK pathway. Eur. J.\u00a0Pharm. Sci. 181: 106348, https:\/\/doi.org\/10.1016\/j.ejps.2022.106348.","DOI":"10.1016\/j.ejps.2022.106348"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_037","doi-asserted-by":"crossref","unstructured":"Li, J., Benashski, S.E., Venna, V.R., and McCullough, L.D. (2010). Effects of metformin in experimental stroke. Stroke 41: 2645\u20132652, https:\/\/doi.org\/10.1161\/strokeaha.110.589697.","DOI":"10.1161\/STROKEAHA.110.589697"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_038","doi-asserted-by":"crossref","unstructured":"Li, H., Liu, R., Liu, J., and Qu, Y. (2024). The role and mechanism of metformin in the treatment of nervous system diseases. Biomolecules 14: 1579, https:\/\/doi.org\/10.3390\/biom14121579.","DOI":"10.3390\/biom14121579"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_039","doi-asserted-by":"crossref","unstructured":"Liu, D., Cao, H., Baranova, A., Xu, C., and Zhang, F. (2025). Opposite causal effects of type 2 diabetes and metformin on Alzheimer\u2019s disease. J.\u00a0Prev. Alzheimers Dis. 12: 100129, https:\/\/doi.org\/10.1016\/j.tjpad.2025.100129.","DOI":"10.1016\/j.tjpad.2025.100129"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_040","doi-asserted-by":"crossref","unstructured":"Liu, K., Li, L., Liu, Z., Li, G., Wu, Y., Jiang, X., Wang, M., Chang, Y., Jiang, T., Luo, J., et al.. (2022). Acute administration of metformin protects against neuronal apoptosis induced by cerebral ischemia-reperfusion injury via regulation of the AMPK\/CREB\/BDNF pathway. Front. Pharmacol. 13: 832611, https:\/\/doi.org\/10.3389\/fphar.2022.832611.","DOI":"10.3389\/fphar.2022.832611"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_041","doi-asserted-by":"crossref","unstructured":"Luo, A., Ning, P., Lu, H., Huang, H., Shen, Q., Zhang, D., Xu, F., Yang, L., and Xu, Y. (2022). Association between metformin and Alzheimer\u2019s disease: a systematic review and meta-analysis of clinical observational studies. J.\u00a0Alzheimers Dis. 88: 1311\u20131323, https:\/\/doi.org\/10.3233\/jad-220180.","DOI":"10.3233\/JAD-220180"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_042","doi-asserted-by":"crossref","unstructured":"Madhusudhanan, J., Suresh, G., and Devanathan, V. (2020). Neurodegeneration in type 2 diabetes: Alzheimer\u2019s as a case study. Brain Behav. 10: e01577, https:\/\/doi.org\/10.1002\/brb3.1577.","DOI":"10.1002\/brb3.1577"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_043","doi-asserted-by":"crossref","unstructured":"Meng, X., Li, D., Kan, R., Xiang, Y., Pan, L., Guo, Y., Yu, P., Luo, P., Zou, H., Huang, L., et al.. (2024). Inhibition of ANGPTL8 protects against diabetes-associated cognitive dysfunction by reducing synaptic loss via the PirB signaling pathway. J.\u00a0Neuroinflamm. 21: 192, https:\/\/doi.org\/10.1186\/s12974-024-03183-8.","DOI":"10.1186\/s12974-024-03183-8"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_044","doi-asserted-by":"crossref","unstructured":"Milori, P.H., Armelin, L.M., Mutarelli, A., and Caramelli, P. (2025). Incidence of dementia in patients with type 2 diabetes using SGLT2 inhibitors versus GLP-1 receptor agonists or DPP-4 inhibitors: a systematic review and meta-analysis of cohort studies. J.\u00a0Alzheimers Dis. 109: 594\u2013603. https:\/\/doi.org\/10.1177\/13872877251395086.","DOI":"10.1177\/13872877251395086"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_045","doi-asserted-by":"crossref","unstructured":"Nath, N., Khan, M., Paintlia, M.K., Singh, I., Hoda, M.N., and Giri, S. (2009). Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J.\u00a0Immunol. 182: 8005\u20138014, https:\/\/doi.org\/10.4049\/jimmunol.0803563.","DOI":"10.4049\/jimmunol.0803563"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_046","doi-asserted-by":"crossref","unstructured":"Nowell, J., Blunt, E., Gupta, D., and Edison, P. (2023). Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res. Rev. 89: 101979, https:\/\/doi.org\/10.1016\/j.arr.2023.101979.","DOI":"10.1016\/j.arr.2023.101979"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_047","doi-asserted-by":"crossref","unstructured":"Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A., and Breteler, M.M. (1999). Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53: 1937\u20131942, https:\/\/doi.org\/10.1212\/wnl.53.9.1937.","DOI":"10.1212\/WNL.53.9.1937"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_048","doi-asserted-by":"crossref","unstructured":"Padhy, D.S., Aggarwal, P., Velayutham, R., and Banerjee, S. (2025). Aerobic exercise and metformin attenuate the cognitive impairment in an experimental model of type 2 diabetes mellitus: focus on neuroinflammation and adult hippocampal neurogenesis. Metab. Brain Dis. 40: 92, https:\/\/doi.org\/10.1007\/s11011-024-01489-3.","DOI":"10.1007\/s11011-024-01489-3"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_049","doi-asserted-by":"crossref","unstructured":"Pakkam, M., Orscelik, A., Musmar, B., Tolba, H., Ghozy, S., Senol, Y.C., Bilgin, C., Nayak, S.S., Kadirvel, R., Brinjikji, W., et al.. (2024). The impact of pre-stroke metformin use on clinical outcomes after acute ischemic stroke: a systematic review and meta-analysis. J.\u00a0Stroke Cerebrovasc. Dis. 33: 107716, https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2024.107716.","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107716"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_050","doi-asserted-by":"crossref","unstructured":"Papini, N., Giussani, P., and Tringali, C. (2024). Metformin lysosomal targeting: a novel aspect to be investigated for metformin repurposing in neurodegenerative diseases? Int. J.\u00a0Mol. Sci. 25: 8884, https:\/\/doi.org\/10.3390\/ijms25168884.","DOI":"10.3390\/ijms25168884"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_051","doi-asserted-by":"crossref","unstructured":"Pomilio, C., P\u00e9rez, N.G., Calandri, I., Crivelli, L., Allegri, R., ADNI Alzheimer\u2019s Disease Neuroimaging Initiative, Sevlever, G., and Saravia, F. (2022). Diabetic patients treated with metformin during early stages of Alzheimer\u2019s disease show a better integral performance: data from ADNI study. GeroScience 44: 1791\u20131805, https:\/\/doi.org\/10.1007\/s11357-022-00568-6.","DOI":"10.1007\/s11357-022-00568-6"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_052","doi-asserted-by":"crossref","unstructured":"Rebelos, E., Bucci, M., Karjalainen, T., Oikonen, V., Bertoldo, A., Hannukainen, J.C., Virtanen, K.A., Latva-Rasku, A., Hirvonen, J., Heinonen, I., et al.. (2021). Insulin resistance is associated with enhanced brain glucose uptake during euglycemic hyperinsulinemia: a large-scale PET cohort. Diabetes Care 44: 788\u2013794, https:\/\/doi.org\/10.2337\/dc20-1549.","DOI":"10.2337\/dc20-1549"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_053","doi-asserted-by":"crossref","unstructured":"Rosell-D\u00edaz, M., Petit-Gay, A., Molas-Prat, C., Gallardo-Nuell, L., Rami\u00f3-Torrent\u00e0, L., Garre-Olmo, J., P\u00e9rez-Brocal, V., Moya, A., Jov\u00e9, M., Pamplona, R., et al.. (2024). Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men. Metabolism 157: 155941, https:\/\/doi.org\/10.1016\/j.metabol.2024.155941.","DOI":"10.1016\/j.metabol.2024.155941"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_054","doi-asserted-by":"crossref","unstructured":"Sayedali, E., Yalin, A.E., and Yalin, S. (2023). Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes. World J.\u00a0Diabetes 14: 585\u2013593, https:\/\/doi.org\/10.4239\/wjd.v14.i5.585.","DOI":"10.4239\/wjd.v14.i5.585"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_055","doi-asserted-by":"crossref","unstructured":"Seminer, A., Mulihano, A., O\u2019Brien, C., Krewer, F., Costello, M., Judge, C., O\u2019Donnell, M., and Reddin, C. (2025). Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis. JAMA Neurol. 82: 450\u2013460, https:\/\/doi.org\/10.1001\/jamaneurol.2025.0360.","DOI":"10.1001\/jamaneurol.2025.0360"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_056","doi-asserted-by":"crossref","unstructured":"Sharma, S., Zhang, Y., Akter, K.A., Nozohouri, S., Archie, S.R., Patel, D., Villalba, H., and Abbruscato, T. (2023). Permeability of metformin across an in\u00a0vitro blood-brain barrier model during normoxia and oxygen-glucose deprivation conditions: role of organic cation transporters (Octs). Pharmaceutics 15: 1357, https:\/\/doi.org\/10.3390\/pharmaceutics15051357.","DOI":"10.3390\/pharmaceutics15051357"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_057","doi-asserted-by":"crossref","unstructured":"Sirtori, C.R., Castiglione, S., and Pavanello, C. (2024). Metformin: from diabetes to cancer to prolongation of life. Pharmacol. Res. 208: 107367, https:\/\/doi.org\/10.1016\/j.phrs.2024.107367.","DOI":"10.1016\/j.phrs.2024.107367"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_058","doi-asserted-by":"crossref","unstructured":"Smith, R.J.Jr, Zollo, R., Kalvapudi, S., Vedire, Y., Pachimatla, A.G., Petrucci, C., Shaller, G., Washington, D., Rr, V., Sass, S.N., et al.. (2025). Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin. J.\u00a0Nat. Cancer Inst. 117: 673\u2013684, https:\/\/doi.org\/10.1093\/jnci\/djae295.","DOI":"10.1093\/jnci\/djae295"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_059","unstructured":"Sterne, J. (1957). Du nouveau dans les antidiab\u00e9tiques. La NN dimethylamine guanyl guanidine (N.N.D.G.) [article in French]. Maroc. Med. 36: 1295\u20131296."},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_060","doi-asserted-by":"crossref","unstructured":"Sun, M., Chen, W.M., Wu, S.Y., and Zhang, J. (2024). Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction. Brain 147: 1474\u20131482, https:\/\/doi.org\/10.1093\/brain\/awad366.","DOI":"10.1093\/brain\/awad366"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_061","doi-asserted-by":"crossref","unstructured":"Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W.M., Wu, S.Y., and Zhang, J. (2025a). Metformin use and risk of delirium in older adults with type 2 diabetes. Diabetes Care 48: 1172\u20131179, https:\/\/doi.org\/10.2337\/dc24-1414.","DOI":"10.2337\/dc24-1414"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_062","doi-asserted-by":"crossref","unstructured":"Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W.M., Wu, S.Y., and Zhang, J. (2025b). Metformin vs. second-line therapy for delirium prevention in type 2 diabetes: a multinational study. Diabetes Res. Clin. Pract. 225: 112270, https:\/\/doi.org\/10.1016\/j.diabres.2025.112270.","DOI":"10.1016\/j.diabres.2025.112270"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_063","doi-asserted-by":"crossref","unstructured":"Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W.M., Wu, S.Y., and Zhang, J. (2025c). Comparative study of SGLT2 inhibitors and metformin: evaluating first-line therapies for dementia prevention in type 2 diabetes. Diabetes Metab. 51: 101655, https:\/\/doi.org\/10.1016\/j.diabet.2025.101655.","DOI":"10.1016\/j.diabet.2025.101655"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_064","doi-asserted-by":"crossref","unstructured":"Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W.M., Wu, S.Y., and Zhang, J. (2025d). Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes. BMJ Open Diabetes Res. Care 13: e004902, https:\/\/doi.org\/10.1136\/bmjdrc-2025-004902.","DOI":"10.1136\/bmjdrc-2025-004902"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_065","doi-asserted-by":"crossref","unstructured":"Sunwoo, Y., Park, J., Choi, C.Y., Shin, S., and Choi, Y.J. (2024). Risk of dementia and Alzheimer\u2019s disease associated with antidiabetics: a Bayesian network meta-analysis. Am. J.\u00a0Prev. Med. 67: 434\u2013443, https:\/\/doi.org\/10.1016\/j.amepre.2024.04.014.","DOI":"10.1016\/j.amepre.2024.04.014"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_066","doi-asserted-by":"crossref","unstructured":"Szablewski, L. (2025). Associations between diabetes mellitus and neurodegenerative diseases. Int. J.\u00a0Mol. Sci. 26: 542, https:\/\/doi.org\/10.3390\/ijms26020542.","DOI":"10.3390\/ijms26020542"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_067","doi-asserted-by":"crossref","unstructured":"Taheri, A., Emami, M., Asadipour, E., Kasirzadeh, S., Rouini, M.R., Najafi, A., Heshmat, R., Abdollahi, M., and Mojtahedzadeh, M. (2019). A randomized controlled trial on the efficacy, safety, and pharmacokinetics of metformin in severe traumatic brain injury. J.\u00a0Neurol. 266: 1988\u20131997, https:\/\/doi.org\/10.1007\/s00415-019-09366-1.","DOI":"10.1007\/s00415-019-09366-1"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_068","doi-asserted-by":"crossref","unstructured":"Tang, H., Guo, J., Shaaban, C.E., Feng, Z., Wu, Y., Magoc, T., Hu, X., Donahoo, W.T., DeKosky, S.T., and Bian, J. (2024). Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: a longitudinal observational study. Alzheimers Dement. 20: 975\u2013985, https:\/\/doi.org\/10.1002\/alz.13480.","DOI":"10.1002\/alz.13480"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_069","doi-asserted-by":"crossref","unstructured":"Tang, C., Hao, J., Tao, F., Feng, Q., Song, Y., and Zeng, B. (2025). Association of metformin use with risk of dementia in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 27: 1992\u20132001, https:\/\/doi.org\/10.1111\/dom.16192.","DOI":"10.1111\/dom.16192"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_070","doi-asserted-by":"crossref","unstructured":"Tian, Y., Jing, G., Ma, M., Yin, R., and Zhang, M. (2024). Microglial activation and polarization in type 2\u00a0diabetes-related cognitive impairment: a focused review of pathogenesis. Neurosci. Biobehav. Rev. 165: 105848, https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105848.","DOI":"10.1016\/j.neubiorev.2024.105848"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_071","doi-asserted-by":"crossref","unstructured":"Tzioras, M., McGeachan, R.I., Durrant, C.S., and Spires-Jones, T.L. (2023). Synaptic degeneration in Alzheimer disease. Nat. Rev. Neurol. 19: 19\u201338, https:\/\/doi.org\/10.1038\/s41582-022-00749-z.","DOI":"10.1038\/s41582-022-00749-z"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_072","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854\u2013865.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_073","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Manrique, R.P., Farina, F., Cambon, K., Dolores Sequedo, M., Parker, A.J., Mill\u00e1n, J.M., Weiss, A., D\u00e9glon, N., and Neri, C. (2016). AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington\u2019s disease. Human Mol. Genetics 25: 1043\u20131058, https:\/\/doi.org\/10.1093\/hmg\/ddv513.","DOI":"10.1093\/hmg\/ddv513"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_074","doi-asserted-by":"crossref","unstructured":"Velazquez, E.M., Mendoza, S., Hamer, T., Sosa, F., and Glueck, C.J. (1994). Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab. Clin. Exp. 43: 647\u2013654, https:\/\/doi.org\/10.1016\/0026-0495(94)90209-7.","DOI":"10.1016\/0026-0495(94)90209-7"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_075","doi-asserted-by":"crossref","unstructured":"Wang, J., Li, L., Zhang, Z., Zhang, X., Zhu, Y., Zhang, C., and Bi, Y. (2022). Extracellular vesicles mediate the communication of adipose tissue with brain and promote cognitive impairment associated with insulin resistance. Cell Metab. 34: 1264\u20131279.e8, https:\/\/doi.org\/10.1016\/j.cmet.2022.08.004.","DOI":"10.1016\/j.cmet.2022.08.004"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_076","doi-asserted-by":"crossref","unstructured":"Wang, M., Zhang, Z., Georgakis, M.K., Karhunen, V., and Liu, D. (2023). The impact of genetically proxied AMPK activation, the target of metformin, on functional outcome following ischemic stroke. J.\u00a0Stroke 25: 266\u2013271, https:\/\/doi.org\/10.5853\/jos.2022.03230.","DOI":"10.5853\/jos.2022.03230"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_077","doi-asserted-by":"crossref","unstructured":"Wei, J., Hu, L., Xu, S., Yang, F., Liao, F., Tang, Y., Shen, X., Zhang, X., Fang, X., Li, Y., et al.. (2025). A liver-specific expression of ANGPTL8 promotes Alzheimer\u2019s disease progression through activating microglial pyroptosis. J.\u00a0Neuroinflamm. 22: 177, https:\/\/doi.org\/10.1186\/s12974-025-03487-3.","DOI":"10.1186\/s12974-025-03487-3"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_078","doi-asserted-by":"crossref","unstructured":"Weinberg, M.S., He, Y., Kivis\u00e4kk, P., Arnold, S.E., and Das, S. (2024). Effect of metformin on plasma and cerebrospinal fluid biomarkers in non-diabetic older adults with mild cognitive impairment related to Alzheimer\u2019s disease. J.\u00a0Alzheimers Dis. 99: S355\u2013S365, https:\/\/doi.org\/10.3233\/jad-230899.","DOI":"10.3233\/JAD-230899"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_079","doi-asserted-by":"crossref","unstructured":"Xie, W., Ding, B., Lou, J., Wang, X., Guo, X., and Zhu, J. (2024). Metformin attenuates white matter injury in neonatal mice through activating NRF2\/HO-1\/NF-\u03baB pathway. Int. Immunopharmacol. 141: 112961, https:\/\/doi.org\/10.1016\/j.intimp.2024.112961.","DOI":"10.1016\/j.intimp.2024.112961"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_080","doi-asserted-by":"crossref","unstructured":"Yang, Y., Lu, X., Liu, N., Ma, S., Zhang, H., Zhang, Z., Yang, K., Jiang, M., Zheng, Z., Qiao, Y., et al.. (2024). Metformin decelerates aging clock in male monkeys. Cell 187: 6358\u20136378.e29, https:\/\/doi.org\/10.1016\/j.cell.2024.08.021.","DOI":"10.1016\/j.cell.2024.08.021"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_081","doi-asserted-by":"crossref","unstructured":"Yang, F., Qin, Y., Wang, Y., Meng, S., Xian, H., Che, H., Lv, J., Li, Y., Yu, Y., Bai, Y., et al.. (2019). Metformin inhibits the NLRP3 inflammasome via AMPK\/mTOR-dependent effects in diabetic cardiomyopathy. Int. J.\u00a0Biol. Sci. 15: 1010\u20131019, https:\/\/doi.org\/10.7150\/ijbs.29680.","DOI":"10.7150\/ijbs.29680"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_082","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, Y., Shi, X., Han, J., Lin, B., Peng, W., Mei, Z., and Lin, Y. (2022). Metformin and the risk of neurodegenerative diseases in patients with diabetes: a meta-analysis of population-based cohort studies. Diabet. Med. 39: e14821, https:\/\/doi.org\/10.1111\/dme.14821.","DOI":"10.1111\/dme.14821"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_083","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Zhang, Y. (2021). GLP-1 receptor agonists: beyond their pancreatic effects. Front. Endocrinol. 12: 721135, https:\/\/doi.org\/10.3389\/fendo.2021.721135.","DOI":"10.3389\/fendo.2021.721135"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_084","doi-asserted-by":"crossref","unstructured":"Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al.. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J.\u00a0Clin. Invest. 108: 1167\u20131174, https:\/\/doi.org\/10.1172\/jci13505.","DOI":"10.1172\/JCI13505"},{"key":"2026070214032334419_j_revneuro-2026-0013_ref_085","doi-asserted-by":"crossref","unstructured":"Zilliox, L.A., Chadrasekaran, K., Kwan, J.Y., and Russell, J.W. (2016). Diabetes and cognitive impairment. Curr. Diab. Rep. 16: 87, https:\/\/doi.org\/10.1007\/s11892-016-0775-x.","DOI":"10.1007\/s11892-016-0775-x"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0013\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0013\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:29:19Z","timestamp":1783006159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0013\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":84,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1515\/revneuro-2026-0013"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2026-0013","relation":{},"ISSN":["0334-1763","2191-0200"],"issn-type":[{"value":"0334-1763","type":"print"},{"value":"2191-0200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}